Company Overview and News

4
MOVES-Tetragon hires Snell as firm considers investments across CLO structure

4h reuters
NEW YORK, Sept 19 (LPC) - Tetragon Credit Income Partners has hired Scott Snell, the former co-head of BlackRock’s US Collateralized Loan Obligation (CLO) business, as it considers new investments.
WFC WFCNP

16
Stein Mart, Inc. Announces Five-Year Extended and Amended $275 Million Credit Agreements

13h globenewswire
JACKSONVILLE, Fla., Sept. 18, 2018 (GLOBE NEWSWIRE) -- Stein Mart, Inc. (NASDAQ: SMRT) (the “Company”) announced today that it has extended and amended its existing revolving credit agreement with Wells Fargo Bank (Wells Fargo) and its term loan agreement with Gordon Brothers Finance Company (GBF). These agreements are coordinated through an intercreditor agreement and provide for combined borrowing availability of $275 million.
WFC WFCNP SMRT

6
Blackrock: Crown Jewel + Hidden Gem = Opportunity

15h seekingalpha
A decade ago, the US was enduring a brutal financial crisis. Many still have memories are bankruptcies, massive losses, home foreclosures, reckless insurers, CDS (credit default swaps) bets and billion-dollar bank bailouts. With the 10-yr anniversary of Lehman Brothers bankruptcy just occurring, most investors remember the losses and pain of the financial crisis. While we learned much from enduring this time-period, as well as the dot-com bust, we thought we would spend some time reviewing a winner from this environment.
WFCNP MGR EV FII BEN MS WFC STT AMG LMHA LMHB BLK LM

18
Refinitiv loans break for trading

16h reuters
NEW YORK, Sept 18 (LPC) - The US$9.25bn in term loans backing private equity firm Blackstone Group’s purchase of a 55% stake in Refinitiv, Thomson Reuters’ Financial and Risk (F&R) division, allocated and broke for trading on Tuesday.
WFCNP BGX DB BGLF MS WFC BX BGB

12
Top Analyst Reports for Walmart, IBM & Texas Instruments

17h zacks
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Walmart (WMT), IBM (IBM) and Texas Instruments (TXN). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
WFCNP SOJA LMT TXN GAS WMT CME WFC SO 7018 URI OXY

4
BRP annonce la clôture du reclassement

20h globenewswire
VALCOURT, Québec, 18 sept. 2018 (GLOBE NEWSWIRE) -- BRP inc. (TSX : DOO; NASDAQ : DOOO) (« BRP » ou la « Société ») a annoncé aujourd’hui la clôture de son reclassement déjà annoncé visant 8 700 000 actions à droit de vote subalterne vendues par certains de ses actionnaires, dont Beaudier Inc. et 4338618 Canada Inc. (collectivement, le « groupe Beaudier ») ainsi que Bain Capital (« Bain »), au prix d’offre de 47,00 $ US par action, pour un produit brut total revenant aux actionnaires vendeurs de 408 900 000 $ US.
WFC WFCNP MS

4
Alterna Capital Solutions Adds $30 Million

21h accesswire
Wells Fargo Capital Finance Credit Line Positions New Firm to Bring Custom, Growth Capital Solutions to Small Businesses Across the U.S.
WFC WFCNP

61
7 Market Heavyweights That Are Quickly Becoming Stocks to Sell

2018-09-18 investorplace - 1
U.S. equities opened lower on Monday, led by weakness in high-profile technology stocks and the U.S. dollar. Investors remained concerned about the likelihood of additional trade tariffs against China on reports President Trump is getting ready to unveil another package of taxes on $200 billion worth of imports.
WFC WFCNP FB GOOG GS GOOGL TWTR DIS MCD

13
Coca Cola eyes cannabis-infused drink market

2018-09-18 moneycontrol
Coca-Cola Co is closely watching the fast-growing marijuana drinks market for a possible entry that would expand the world's largest soft drink maker's ambitions further away from sugary sodas.
WFC WFCNP STZ.B ACBFF STZ ACB KO

4
Coke eyes cannabis-infused drink market

2018-09-17 thestar.com.my
Wells Fargo analyst Bonnie Herzog called the news "an exciting potential development" as it would take Coke into another fast-growing healthier segment following last month's $5.1 billion deal for Costa Coffee and expand cannabis-infused drinks in the area of functional wellness products.
WFC WFCNP

10
Is Spotify King Of The Music World? Top Analysts Chime In

2018-09-17 seekingalpha
Spotify (SPOT) is a Swedish on-demand music streaming giant with the world at its feet. After all, after first bursting onto the scene in 2008, Spotify now rules the industry across the globe.
WFC WFCNP P

7
Ally Versus BofI - Which Internet Bank Should You Own?

2018-09-17 seekingalpha
Capital return to shareholders in the form of dividends and share buybacks offer Ally investors a degree of safety.
WFC WFCNP NIM BOFI ALLY BOFIL

19
You Should Sell Coca-Cola

2018-09-17 seekingalpha - 1
Coca-Cola has an extremely strong consumer franchise, and the company is here to stay. At current valuation levels though, the shares are a sell.
WFC WFCNP PM KDP RAI JPM KO MO

9
The Valuation of Citigroup Stock Is Quite Attractive

2018-09-17 investorplace
Citigroup (NYSE:C) is having a fairly uneventful 2018 so far, at least as far as its stock goes. Since February, Citigroup stock has traded in a tight range between $65 and $75 per share.
WFC WFCNP C TNTTF TD TD

58
9/15/2018: 10th Anniversary Of The Lehman Bankruptcy

2018-09-17 seekingalpha
Ten Years that feel like an eternity and through which the markets have erased almost any remnant for what happened.
WFCNP NFLX NVDA BAC AAPL MS WFC BAC C NYTAB MSFT

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 949746879